Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in Type 2 diabetes mellitus

被引：0
作者：
Kelley, DE [1 ]
McKolanis, TM [1 ]
Kelley, CA [1 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
583
引用
收藏
页码：A188 / A188
页数：1
相关论文
共 50 条
[31]   Relationship of visceral and subcutaneous adiposity with renal function in people with type 2 diabetes mellitus [J].
Kim, Sung Rae ;
Yoo, Ji Han ;
Song, Ho Cheol ;
Lee, Seong Su ;
Yoo, Soon Jib ;
Kim, Young-Du ;
Lim, Yeon Soo ;
Kim, Hyung Wook ;
Yang, Chul Woo ;
Kim, Yong-Soo ;
Choi, Euy Jin ;
Kim, Yong Kyun .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (11) :3550-3555
[32]   Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes [J].
Stage, Tore Bjerregaard ;
Christensen, Mette-Marie Hougaard ;
Jorgensen, Niklas Rye ;
Beck-Nielsen, Henning ;
Brosen, Kim ;
Gram, Jeppe ;
Frost, Morten .
BONE, 2018, 112 :35-41
[33]   Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2 [J].
Petersen, KU .
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2004, 54 (01) :20-30
[34]   Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus [J].
Banerji, M ;
Lebovitz, H ;
Dugbartey, M .
DIABETES, 2001, 50 :A90-A90
[35]   The impact of therapy with rosiglitazone (RSG) versus metformin (MET) on liver associated enzymes (LAEs) in patients with type 2 diabetes mellitus [J].
Mann, K ;
Mulhall, B ;
Maydonovitch, C ;
Stocker, D ;
Vigersky, R ;
Holtzmuller, K .
GASTROENTEROLOGY, 2004, 126 (04) :A757-A757
[36]   Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes [J].
Iozzo, P ;
Hallsten, K ;
Oikonen, V ;
Virtanen, KA ;
Parkkola, R ;
Kemppainen, J ;
Solin, O ;
Lonnqvist, F ;
Ferrannini, E ;
Knuuti, J ;
Nuutila, P .
DIABETES CARE, 2003, 26 (07) :2069-2074
[37]   Effects of Rosiglitazone vs Metformin on Circulating Osteoclast and Osteogenic Precursor Cells in Postmenopausal Women with Type 2 Diabetes Mellitus [J].
Rubin, M. R. ;
Manavalan, J. S. ;
Agarwal, S. ;
McMahon, D. J. ;
Nino, A. ;
Fitzpatrick, L. A. ;
Bilezikian, J. P. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (10) :E1933-E1942
[38]   Metformin for Type 2 diabetes mellitus [J].
MacDonald, Blair J. ;
Turgeon, Ricky D. ;
McCormack, James .
ACADEMIC EMERGENCY MEDICINE, 2024, 31 (08) :832-834
[39]   Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome [J].
Derosa, G ;
Gaddi, AV ;
Piccinni, MN ;
Ciccarelli, L ;
Salvadeo, S ;
Peros, E ;
Ghelfi, M ;
Ferrari, I ;
Cicero, AFG .
PHARMACOTHERAPY, 2005, 25 (05) :637-645
[40]   The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment [J].
Cariou, Bertrand .
DIABETES OBESITY & METABOLISM, 2022, 24 :15-27
12345